On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. After certain milestones were achieved, BioGaia has extended its ownership to 92 percent of the shares in MetaboGen. The additional thirty percent was purchased for a little over $3 million.

BioGaia intends to acquire the remaining 8 percent in the company within a three year period. Based on how many milestones might be achieved, the additional shares could be priced at a maximum of $1.37 million.

BioGaia is a Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in 100 countries worldwide.

MetaboGen is developing next generation probiotics for treating a number of diseases and conditions.

To keep up with the latest in the dynamic and fast growing microbiome industry subscribe to our premium newsletter or our microbiome database. Both include access to the microbiome database and our weekly microbiome newsletter.